ZYUS Life Sciences amends promissory note agreement

ZYUS Life Sciences Corporation has amended a Promissory Note Agreement with an independent director, replacing it with a new loan agreement. The new agreement increases the principal amount from $0.1 million to $0.375 million and extends the maturity date to March 28, 2027. The loan includes an additional cash advance of $0.25 million and capitalizes $0.025 million of unpaid interest. The loan bears an annual interest rate of 12% and is pre-payable without penalty. The lender will receive 281,250 warrants to purchase common shares at $0.80 each. This transaction is classified as a related party transaction, with the lender abstaining from the approval vote. The company has relied on exemptions from certain regulatory requirements and did not file a material change report prior to the loan's issuance.